Yuhan Corporation (000100.KS) Stock

000100.KS logo

Yuhan Corporation

000100.KSSouth Korea
Healthcare

Company profile

Yuhan reported revenue of 2.07 trillion KRW for fiscal year 2024, up 11.2% from fiscal year 2023, and net income of 70.69 billion KRW. That is a net profit margin of 3.4% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 578.99 billion KRW, up 9.6% from a year before. In Q2 2025 it reported net income of 45.53 billion KRW, against net income of 32.06 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 1.78 trillion KRW in fiscal year 2022 to 2.07 trillion KRW in fiscal year 2024, 7.9% a year on average. Yuhan reports about 2,082 full-time employees.

What stands out

  • Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2024.

About Yuhan Corporation

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom synthesis services through commercial supply in areas of anti-viral, anti-HIV, anti-HCV, anti-biotic, antihistamine, anti-diabetic, ß-lactamase inhibitor, CNS intermediate, PEG-compounds, and others. Yuhan Corporation was founded in 1926 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Yuhan Foundation17.24%
  • Yuhan Corporation8.19%
  • National Pension Service of Korea7.39%
  • BlackRock Fund Advisors4.24%
  • Sang Ho Lee2.033 %2.03%

Share of the company, as of September 25, 2026

Leadership

  • Wook-Je Cho — President, CEO & Executive Director, 70
  • Yeul-Hong Kim — President, R&D Director & Executive Director, 66
  • Byung-Man Lee — VP, Head of the Mngt. HQ. & Internal Accounting Manager, 67
  • Eunhee Park — MD & Director of Legal Affairs, 54
  • Joo-Yong Chung — MD & Head of Marketing Department, 58

How much revenue does Yuhan make?

Yuhan reported 2.07 trillion KRW in revenue for fiscal year 2024, up 11.2% from 1.86 trillion KRW in fiscal year 2023. In Q2 2025 revenue was 578.99 billion KRW.

What companies are similar to Yuhan?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Alteogen Inc. (196170.KQ), Hanmi Pharm. Co., Ltd. (128940.KS), Hanall Biopharma Co., Ltd. (009420.KS), LigaChem Biosciences Inc. (141080.KQ).

How has Yuhan's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, 1.62 trillion KRW; FY2021, 1.69 trillion KRW; FY2022, 1.78 trillion KRW; FY2023, 1.86 trillion KRW; FY2024, 2.07 trillion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees2,082
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
74, Noryangjin-ro, Seoul
Phone
82 2 828 0181
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Yuhan Corporation (000100.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/000100.KS

LinkedInLinkedInXXYouTubeYouTube